Patrick J. Cimino

Patrick J. Cimino

Allergy and Immunology

111 Michigan Avenue Northwest
Washington, DC 20010

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 113 publications

Loss of MSH6 or MSH2 sensitizes progressive glioblastoma to radiotherapy.

Loss of MSH6 or MSH2 sensitizes progressive glioblastoma to radiotherapy.

Journal: The Journal of clinical investigation

Published: August 25, 2026

Sellar region neurocytomas exhibit a CIMP and neuroendocrine-like epigenetic signature distinct from other intra-axial neurocytomas.

Sellar region neurocytomas exhibit a CIMP and neuroendocrine-like epigenetic signature distinct from other intra-axial neurocytomas.

Journal: Acta neuropathologica

Published: July 02, 2026

A fluorescein-conjugated somatostatin receptor antagonist adapter for chimeric antigen receptor T cell therapy of meningioma.

A fluorescein-conjugated somatostatin receptor antagonist adapter for chimeric antigen receptor T cell therapy of meningioma.

Journal: Neuro-oncology advances

Published: March 17, 2026

SLC44A1::PRKCA fusion-positive glioneuronal tumor without histological and epigenetic features of papillary glioneuronal tumor.

SLC44A1::PRKCA fusion-positive glioneuronal tumor without histological and epigenetic features of papillary glioneuronal tumor.

Journal: Journal of neuropathology and experimental neurology

Published: November 13, 2025

Integrated high-resolution copy number and histomolecular analysis of diffuse hemispheric glioma, H3 G34-mutant reveals universal TP53 abnormalities.

Integrated high-resolution copy number and histomolecular analysis of diffuse hemispheric glioma, H3 G34-mutant reveals universal TP53 abnormalities.

Journal: Brain pathology (Zurich, Switzerland)

Published: October 18, 2025

Characterization of MAIT cells in glioblastoma reveals a potential immunosuppressive role through a MAIT-neutrophil axis.

Characterization of MAIT cells in glioblastoma reveals a potential immunosuppressive role through a MAIT-neutrophil axis.

Journal: Neuro-oncology advances

Published: October 01, 2025

Molecular, histologic, and clinical characterization of methylation class pleomorphic xanthoastrocytoma: An analysis of 469 tumors.

Molecular, histologic, and clinical characterization of methylation class pleomorphic xanthoastrocytoma: An analysis of 469 tumors.

Journal: Neuro-oncology advances

Published: July 30, 2025

PDE10A as a novel diagnostic and therapeutic target in cancer: insights and challenges.

PDE10A as a novel diagnostic and therapeutic target in cancer: insights and challenges.

Journal: Frontiers in oncology

Published: July 19, 2025

Classification accuracy of a hierarchical molecular inference-based deep-learning system for CNS tumour diagnosis: a multi-institutional, retrospective study.

Classification accuracy of a hierarchical molecular inference-based deep-learning system for CNS tumour diagnosis: a multi-institutional, retrospective study.

Journal: The Lancet. Oncology

Published: July 01, 2025

Loss of PDE10A is associated with metastasis of colon adenocarcinoma.

Loss of PDE10A is associated with metastasis of colon adenocarcinoma.

Journal: Histology and histopathology

Published: June 23, 2025

FGFR1 fusions in genomically and epigenetically bona fide glioblastoma, IDH-wildtype.

FGFR1 fusions in genomically and epigenetically bona fide glioblastoma, IDH-wildtype.

Journal: Journal of neuropathology and experimental neurology

Published: June 12, 2025

C-terminal fusion partner activity contributes to the oncogenic functions of YAP1::TFE3.

C-terminal fusion partner activity contributes to the oncogenic functions of YAP1::TFE3.

Journal: Scientific reports

Published: May 09, 2025

Showing 1-12 of 113

Last Updated: 09/26/2026